Glucocorticoid Induced Leucine Zipper in Lipopolysaccharide Induced Neuroinflammation.

Front Aging Neurosci

Department of Oral Pathology, Medicine and Radiology, Indiana University School of Dentistry and Indiana University-Purdue University Indianapolis, Indiana University School of Medicine, Indianapolis, IN, United States.

Published: January 2019

Glucocorticoids (GCs) are steroid hormones secreted as the end-product of the neuroendocrine stress cascade. Both absence and elevated GC mediate neurotoxic responses, suggesting that a narrow window ranging from physiological to slightly high GC mediate protective responses. The beneficial effects of GC are attributed to the transactivation of regulatory proteins and inhibition mediated by glucocorticoid receptor (GR) interactions with other co-factors. The glucocorticoid induced leucine zipper (GILZ) is a gene strongly upregulated by GC and mediates many of the anti-inflammatory and anti-proliferative effects of GC. Although GILZ is constitutively expressed in many tissues including the brain, the expression has been shown to occur with varying dynamics suggesting that the local milieu modulates its expression with consequent effects on cellular responses. Here we investigated the expression profile of GILZ in lipopolysaccharide (LPS) mediated neuroinflammation model of Alzheimer's disease (AD). Our data suggest that the GILZ expression is downregulated in neuroinflammation correlating inversely with the pro-inflammatory cytokines and innate immune responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355683PMC
http://dx.doi.org/10.3389/fnagi.2018.00432DOI Listing

Publication Analysis

Top Keywords

glucocorticoid induced
8
induced leucine
8
leucine zipper
8
zipper lipopolysaccharide
4
lipopolysaccharide induced
4
induced neuroinflammation
4
neuroinflammation glucocorticoids
4
glucocorticoids gcs
4
gcs steroid
4
steroid hormones
4

Similar Publications

Patients with A20 haploinsufficiency (HA20) presenting with central nervous system (CNS) symptoms are rare, and available reports are limited. Here, we describe a patient with HA20, previously followed up as Behçet disease, who presented with CNS symptoms in adulthood. A 38-year-old Japanese male who had been followed up for incomplete Behçet disease at another hospital since 28 years of age presented to our hospital with acute-onset diplopia and persistent hiccups that were severe enough to cause vomiting.

View Article and Find Full Text PDF

[Clinical analysis of 6 cases of induced rash and mucositis in children].

Zhonghua Er Ke Za Zhi

January 2025

Department of Gastroenterology and Infectious Diseases, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai200062, China.

To summarize the clinical features, laboratory findings, treatment and prognosis of children confirmed as -induced rash and mucositis (MIRM) in children. This retrospective study concluded 6 children diagnosed as MIRM in Department of Gastroenterology and Infectious Diseases, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University from August 2023 to April 2024. This paper described the characteristics of MIRM and analyzed the therapeutic strategy and prognosis.

View Article and Find Full Text PDF

Background: Glucocorticoids are frequently employed in systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus nephritis (LN), despite their many side effects, including steroid-induced diabetes (SID). Information regarding SID in SLE patients is quite scant.

Purpose: The aim of this study was to determine risk factors associated with the development of SID in patients with LN.

View Article and Find Full Text PDF

Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!